logo
  Join        Login             Stock Quote

Gen-Probe (GPRO)'s PANTHER Testing System Gets FDA Clearance

 May 08, 2012 08:59 AM
 


(By Balachander) Gen-Probe Inc. (NASDAQ:GPRO), a manufacturer of molecular diagnostic products, announced approval from the U.S. health regulators for the company's PANTHER testing system.

The San Diego, California-based company's PANTHER system fully automates all aspects of nucleic acid testing (NAT) on a single, integrated platform, according to the company Web site.

The PANTHER system can initially be used to test for the common sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae with the APTIMA Combo 2 assay, the company said.

Gen-Probe said the approval from the U.S. Food and Drug Administration (FDA) will significantly increase its addressable market domestically, following on the successful international launch of PANTHER in late 2010.

[Related -How Bayer Could Benefit From Potential Warner Chilcott Buyout]

The PANTHER system builds on the success of Gen-Probe's TIGRIS instrument, a NAT system for diagnostics and blood screening.

"The unique capabilities of future versions of the PANTHER system will provide Gen-Probe with the opportunity to enter new and attractive markets in the future such as viral load testing," Gen-Probe said in a statement.

The company will commence shipments of PANTHER systems to US customers during the second quarter of 2012. 

GRPO shares closed Monday's regular trading at $81.39. Over the past year, the stock has been trading between $53.92 and $86.96.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article image3 US Updates Show Ongoing Growth

Three economic updates today provide more evidence that moderate growth endures for the US. The numbers du read on...

article imageBuy These Solar Stocks Before They Snapback

Sometimes the market hands you a gift. And it would be foolish not to take it. Thanks to general market read on...

article imageInvestors Are Even More Euphoric And Confident.

As noted on the blog last Thursday, even though the market had been down for three straight weeks, last read on...

article imageThe Butterfly Machine

There’s a phenomenon called the Butterfly Effect. One common quotation is “It has been said that something read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.